Found 39 Enz. Inhib. hit(s) with all data for entry = 9084 
Affinity DataIC50: 17nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 18nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 27.4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 28nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 31nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 33.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 38.4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 45nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 53.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 61.8nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 63.5nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 71.7nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 76.2nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 92nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 100nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 116nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 136nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 185nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 253nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 275nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 364nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 382nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 392nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 400nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 487nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 591nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 889nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 1.75E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 3.38E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 6.98E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 7.31E+3nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
TargetNuclear receptor subfamily 2 group C member 2(Homo sapiens (Human))
Dana-Farber Cancer Institute, Inc.
US Patent
Dana-Farber Cancer Institute, Inc.
US Patent
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
Affinity DataIC50: 1.00E+4nMAssay Description:The in vitro activity of the compounds described herein in inhibiting TAK1, HCK and other kinases were obtained using an Invitrogen Select Screening ...More data for this Ligand-Target Pair
